Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 3 2Phase 2 2Phase 1 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Carcinoma, Non-Small-Cell Lung 3Prostatic Neoplasms 2Nasopharyngeal Carcinoma 2Glioma 2Glioblastoma 2Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Resectable Lung Non-Small Cell Carcinoma 1Radiation Injuries 1Pancreatic Neoplasms 1Oligodendroglioma 1Neoplasm Metastasis 1Lymphoma, T-Cell, Peripheral 1Lung Neoplasms 1Gastroesophageal Junction Adenocarcinoma 1Frailty 1Chordoma 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1Astrocytoma 1

Interventions

Trastuzumab 304Paclitaxel 257Cyclophosphamide 251Docetaxel 238Capecitabine 176Letrozole 163Carboplatin 163Fulvestrant 145Doxorubicin 145Bevacizumab 121Anastrozole 106Tamoxifen 102exemestane 94Vinorelbine 91Epirubicin 90pertuzumab 89Gemcitabine 84Lapatinib 80Albumin-Bound Paclitaxel 74Radiotherapy 71pembrolizumab 70palbociclib 64130-nm albumin-bound paclitaxel 58eribulin 56Cisplatin 55Everolimus 49pyrotinib 45Taxes 44Goserelin 43Neoadjuvant Therapy 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Breast Neoplasms × Protons × Clear all
NCT01245712 2026-05-01

Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
200 enrolled
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT04717531 2021-06-04

Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Unknown
60 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡